Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mNGF for Prevention and Treatment of Critical Illness Myopathy
ChiCTR-IIR-17010724Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mouse nerve growth factor in acute quadriplegic myopathy (CIM) and Critical Illness Polyneuropathy (CIP) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: compound muscle action potential of median nerve and common peroneal nerve. Started Feb 2017; status: recruiting.
02
Drugs
mouse nerve growth factor
03
Conditions
acute quadriplegic myopathy (CIM)Critical Illness Polyneuropathy (CIP)
Beyond the preview
Go deeper on ChiCTR-IIR-17010724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17010724.